Skip to main navigation
Codiak Biosciences

Investor Relations - Top Nav

  • Our Science

    Our Science

    Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.

    • Exosomes Explained
    • engEx™ Platform
    • Targeted Administration
    • Publications & Presentations
  • Manufacturing
  • Pipeline & Programs

    Pipeline & Programs

    We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.

    • Pipeline
    • exoSTING™
    • exoIL-12™
    • exoASO-STAT6™
  • About Us

    About Us

    At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.

    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Careers
  • Investors & Media

    Investors & Media

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • Investor Resources

SEC Filing Details

SEC Filing Details

Document Details

Form
D
Filing Date
Nov 25, 2015
Document Date
Nov 25, 2015
Filing Group
Other
Company
Codiak BioSciences
Issuer
Codiak BioSciences, Inc.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2022 All Rights Reserved.

Footer Links

  • Contact
  • Privacy Policy
  • Terms of Use
LinkedIn Twitter